[
    "{\"step_by_step_thinking\": \"This study is an open-labeled clinical trial. It is open-labeled because all patients are informed that they would be treated with the tyrosine kinase inhibitor, and there is no blinding of treatment assignment. It is a clinical trial because it involves the evaluation of a new treatment (tyrosine kinase inhibitor) in patients with chronic myeloid leukemia in blast crisis. The study is not a case-control study because it does not involve comparing patients with the disease to a control group. It is also not a crossover study because there is no switching of treatments or comparison of different treatment sequences. Finally, it is not a randomized clinical trial because patients are not randomly assigned to different treatment groups.\", \"answer_choice\": \"C. Open-labeled clinical trial\"}"
]